Core Viewpoint - The record-breaking licensing agreement between 3SBio and Pfizer, valued at up to $60.5 billion, marks a significant milestone for Chinese pharmaceutical companies in the global market [1][2]. Group 1: Company Developments - 3SBio announced an exclusive licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, granting Pfizer global rights (excluding mainland China) for development, production, and commercialization [1]. - The agreement includes an upfront payment of $12.5 billion, which sets a new record for upfront payments for Chinese dual antibodies going abroad, along with potential milestone payments of up to $48 billion based on development, registration, and sales [1]. - The drug SSGJ-707 has received breakthrough therapy designation from the National Medical Products Administration for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression [1]. Group 2: Market Impact - Following the announcement, 3SBio's stock surged by 32.28%, while its A-share counterpart, 3SBio Guojian, rose by 19.99%, reflecting heightened investor interest in the innovative drug sector [2]. - Other innovative drug stocks in the Hong Kong market also saw significant gains, with Rongchang Bio up 16.19% and Hansoh Pharmaceutical up 5.74% [2]. - The innovative drug sector's momentum led to increased trading activity in related ETFs, with one ETF recording a transaction volume of 28.28 billion yuan and closing up 5.16% [2]. Group 3: Industry Trends - According to Wanlian Securities, the domestic innovative drug sector is expected to benefit from favorable policies and industry trends, leading to a valuation recovery [3]. - The importance of Chinese pharmaceutical companies is growing in international academic conferences, with many multinational corporations incorporating Chinese products into their core pipelines [3]. - Despite recent market fluctuations due to U.S. drug pricing policies, several domestic brokerages maintain a positive outlook on the growth potential of innovative drug companies in both the Hong Kong and A-share markets [3].

Group 1 - The core point of the news is the significant rise in the innovative drug sector, driven by the announcement of a collaboration between 3SBio and Pfizer, resulting in a $6.05 billion deal, which has positively impacted the entire sector [2] - Following the announcement, 3SBio's stock surged over 35%, creating a ripple effect that boosted the stock prices of other pharmaceutical companies like CSPC Pharmaceutical Group and Innovent Biologics [2] - The innovative drug sector has seen increased trading volume, indicating heightened market activity and investor interest, which could lead to further price increases [4] Group 2 - Market confidence in the innovative drug sector has strengthened due to 3SBio's success, leading investors to believe in the potential for future growth and investment opportunities [5] - The aging population and the growing demand for medication present significant opportunities for the pharmaceutical sector, particularly in innovative drugs combined with AI [6] - The investment strategy suggested includes long-term commitment and regular investments in funds related to the innovative drug sector, as the potential for returns is promising [6][7]

三连跌后，港股终于迎来反弹。 周二，港股三大指数高开高走，市场热点轮动加速，生物医药、创新药等板块发起强势猛攻。 | ● 热力图 ○ 列表 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | Wind香港概念板块指数 | | | Wind香港二级行业指数 | | | | | | 影视传媒 | 抗肿瘤 | 创新药 | 本地券商 | 黄金珠宝 | Wind香港电气设 Wind香港医药生 Wind香港家庭用 Wind香港硬件设 Wind香港传 | | | | | | 5.73% | 4.96% | 4.82% | 4.69% | 4.40% | 13.40% | 4.05% | 3.84% | 2.48% | 1.59% | | 智能家居 | 武汉本地 | 生物医疗 | CRO | 智能终端 | Wind香港汽车与 Wind香港电信服 Wind香港环保II Wind香港有色金 Wind香港家中 | | | | | | 3.82% | 3.80% | 3.75% | 3.43% | 3.38% ...

第二，大中型药企经营业绩向上趋势明显。创新药企业整体已进入扭亏为盈区间，利润转正后未来几年 将进入非线性地高速增长阶段。同时在产业内，外资药企购买中国创新药品种趋势明显，中国创新药资 产在全球视角下处于显著低估，产业趋势临界点有望到来。 第三，政策端有明显支持的新动作。今年医保谈判时间提前，医保谈判和丙类目录调整同步进行，丙类 目录主要纳入创新程度高的产品，展现国家支持创新药发展、支持商保作为第二支付手段的决心。 上支付宝APP搜：天弘恒生沪深港创新药精选50ETF联接（C类：014565）一键打包三地创新药龙头 股，天弘国证生物医药ETF联接（C类：011041）汇聚医药各行业龙头，有望助您把握本轮医药反弹行 情。 【后市解读：医药板块后市怎么看？—天弘基金】 4月以来，市场风向开始逐渐转向创新药，创新药相关指数在全市场表现靠前。天弘基金认为：基于基 本面和估值的角度，医药是当前全市场性价比非常高的行业。 第一，看好国产创新药的整体机会。总体上创新药产业已经历 4 年下行，前期医保谈判导致预期过度悲 观，目前政策转向空间及需求相对迫。过去几个月，行业内始终有对优化药品集采政策的广泛讨论和相 应的优化方案征求 ...

Group 1 - The Hong Kong innovative drug sector experienced significant growth, with notable stock increases for companies such as Sangfor Pharma (up 36%), CSPC Pharmaceutical (up over 8%), and others [1] - Various ETFs tracking the innovative drug sector also saw substantial gains, with increases ranging from 4.72% to 5.23% [1][3] Group 2 - Sangfor Pharma announced a licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [5] - This licensing deal sets a new record for upfront payments for Chinese bispecific antibodies, indicating strong market interest [5][6] Group 3 - The trend of Chinese innovative drug companies expanding internationally continues, with multiple successful licensing deals occurring despite recent trade tensions [7] - Recent examples include CSPC Pharmaceutical's licensing of irinotecan liposome injection to Cipla USA for $15 million upfront and potential milestone payments exceeding $1 billion [8] Group 4 - Market analysts believe that multinational corporations' interest in acquiring Chinese innovative drug assets remains strong, which will drive further international expansion [11] - Upcoming ASCO conference will feature significant data releases from several innovative drug companies, including Sangfor Pharma and Innovent Biologics [11] Group 5 - The innovative drug sector is expected to enter a rapid growth phase, driven by commercialization efforts and licensing agreements, which will enhance revenue and accelerate profitability [12] - Sangfor Pharma holds a significant weight in various indices, with a 4.38% share in the Hang Seng Hong Kong Stock Connect Innovative Drug Index [12][17] Group 6 - Analysts predict that high-quality innovative drug companies are entering a profitability cycle, supported by continuous performance releases and favorable policies [19] - The overall supply-demand dynamics in the industry are improving, suggesting a favorable investment opportunity in the sector [19]

中国基金报记者卢鸰 中国创新药出海又有大消息。 5月20日早间，三生制药（01530.HK）发布公告称，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性PD-1/VEGF双特异性抗体SSGJ-707在全球（不包括中 国内地）的开发、生产、商业化权利。公司及沈阳三生将保留SSGJ-707在中国内地的开发、生产、商 业化权利，并基于届时商定的财务条款，授予辉瑞对SSGJ-707在中国内地开展商业化的选择权。 根据协议，三生制药将获得12.5亿美元不可退还且不可抵扣的首付款，以及最高可达48亿美元的开发、 监管批准和销售里程碑付款。公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值1亿美元的普通股股份。 国盛证券医药研究团队认为，此次三生制药与辉瑞的合作，其首付款、里程碑等均超预期；中国的第二 波创新药浪潮已经到来，这是中国创新药出海"从0到1"的浪潮。 SSGJ-707是三生制药基于CLF2专利平台开发的靶向PD-1/VEGF双特异性抗体，可同时抑制PD-1和 VEGF双靶点，具有同类最优（best-in-class） ...

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong technology sector, with the CSI Hong Kong Stock Connect Technology Index rising by 1.68% as of May 20, 2025, and notable increases in individual stocks such as 33.24% for 3SBio and 5.31% for Li Auto [1] - The Hong Kong Technology ETF has shown a weekly increase of 0.30% and ranks in the top 1/5 among comparable funds, indicating a positive trend in the technology sector [1] - The trading volume of the Hong Kong Technology ETF reached 48.54 million yuan, with a turnover rate of 8.09%, reflecting strong liquidity in the market [1] Group 2 - 3SBio has entered into an exclusive licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody, which is expected to enhance its market position and revenue potential [2] - The pharmaceutical industry is anticipated to experience valuation recovery in 2025, driven by factors such as innovative drug exports, optimization of domestic procurement policies, and the implementation of new medical insurance directories [2] - The CSI Hong Kong Stock Connect Technology Index comprises 50 large-cap technology companies with high R&D investment and revenue growth, indicating a focus on leading firms in the sector [2][3] Group 3 - As of April 30, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Technology Index account for 71.55% of the index, with major players including Xiaomi, Alibaba, and Tencent [3]

Group 1 - The core viewpoint of the news highlights the positive performance of the Hong Kong Stock Connect Technology ETF (513860), which rose by 1.29% to a price of 0.71 yuan, with a trading volume of 20.75 million yuan as of May 20, 2025 [1] - Notable constituent stocks include 3SBio, which increased by over 29%, and other companies like Innovent Biologics, Zai Lab, and Li Auto, which saw gains of over 4% [1] - On May 19, 2025, 3SBio entered into an exclusive licensing agreement with Pfizer, granting Pfizer global rights to the PD-1/VEGF bispecific antibody (code: SSGJ-707) and commercialization rights in China [1] - CMB International anticipates that the pharmaceutical industry will experience valuation recovery in 2025, driven by factors such as innovative drug exports, optimization of domestic procurement policies, and the implementation of innovative drug insurance catalog [1] Group 2 - The latest scale of the Hong Kong Stock Connect Technology ETF reached 1.89 billion yuan [2] - Over the past 18 trading days, the ETF has attracted a total of 385 million yuan in inflows [2] - The ETF closely tracks the CSI Hong Kong Stock Connect Technology RMB Index, which selects 50 large-cap, high R&D investment, and high revenue growth technology leading companies from the Hong Kong Stock Connect universe [1]

Group 1 - The Hong Kong stock market opened strong on May 20, with the Hong Kong Innovation Drug ETF (159570) rising over 3.6% and quickly surpassing a transaction volume of 4 billion [1] - The Hong Kong Innovation Drug ETF has seen a net inflow of over 2.2 billion in the last 60 days, indicating strong investor interest in the innovative drug sector [1] - On May 20, 2023, 3SBio announced a partnership with Pfizer, granting exclusive rights for the global development, production, and commercialization of its proprietary PD-1/VEGF bispecific antibody SSGJ-707 outside of mainland China [1] Group 2 - According to the agreement, 3SBio will receive a non-refundable upfront payment of $1.25 billion and up to $4.8 billion in milestone payments related to development, regulatory approval, and sales [1] - 3SBio will also receive a tiered sales royalty based on product sales in the licensed territories, and Pfizer will purchase $100 million worth of common stock in 3SBio upon the agreement's effective date [1] - The majority of the popular component stocks in the Hong Kong Innovation Drug ETF saw gains, with 3SBio rising over 30% [3] Group 3 - The 2025 ASCO Annual Meeting, recognized as a major oncology conference, will take place from May 30 to June 3, 2025, in Chicago, Illinois [3] - Several innovative drug companies are expected to disclose significant data at the ASCO meeting, with 3SBio set to present Phase 2 data for SSGJ-707 in non-small cell lung cancer [3] - The recent U.S. drug price reduction executive order may lead to global pharmaceutical companies adjusting their pricing strategies, with China's innovative drugs potentially becoming a preferred choice for business development transactions [4][5] Group 4 - The U.S. executive order aims to provide the best price for prescription drugs, but its short-term impact on innovative drug prices is expected to be limited due to the lack of implementation details and potential legal challenges [5] - Long-term pressures on U.S. drug prices are anticipated as Medicare and Medicaid expenditures are projected to grow from $1.5 trillion to $2.0 trillion from 2020 to 2024, with an annual growth rate of 7.0% [5] - The Hong Kong Innovation Drug ETF (159570) has a high concentration in innovative drugs, with over 85% of its weight in innovative drug stocks, making it a prominent player in the market [6]

截至2025年5月20日 09:37，中证港股通医药卫生综合指数(930965)强势上涨3.03%，石药集团(01093)上涨6.90%，先声药业(02096)上涨6.67%，康哲药业 (00867)，诺诚健华(09969)等个股跟涨。 港股医药ETF(159718)上涨3.10%， 冲击3连涨。最新价报0.73元。拉长时间看，截至2025年5月19日，港股医药ETF近1周累计上涨3.50%。 截至2025年5月20日 09:37，中证医药及医疗器械创新指数(931484)强势上涨1.33%，成分股华海药业(600521)上涨10.00%，川宁生物(301301)上涨5.37%，科 伦药业(002422)上涨4.78%，神州细胞(688520)，智飞生物(300122)等个股跟涨。医疗创新ETF(516820)上涨0.87%，最新价报0.35元。拉长时间看，截至2025 年5月19日，医疗创新ETF近1周累计上涨1.48%。 流动性方面，医疗创新ETF盘中换手0.76%，成交1194.23万元。拉长时间看，截至5月19日，医疗创新ETF近1年日均成交4774.83万元。 流动性方面，港股医药ETF盘中换手4. ...